422270-29-9

Basic information

• Product Name: Piperazine, 1-[(4-fluorophenyl)methyl]-3-methyl-, (3R)-
• CAS NO: 422270-29-9
• Molecular Formula: C12H17FN2
• Molecular Weight: 208.279
• Mol File: 422270-29-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Piperazine, 1-[(4-fluorophenyl)methyl]-3-methyl-, (3R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 1-[(4-fluorophenyl)methyl]-3-methyl-, (3R)-(422270-29-9)
• EPA Substance Registry System: Piperazine, 1-[(4-fluorophenyl)methyl]-3-methyl-, (3R)-(422270-29-9)

Safety Data

• Hazardous Substances Data: 422270-29-9(Hazardous Substances Data)

Upstream product

• 75336-86-6 (2R)-methylpiperazine 
• 352-11-4 1-chloromethyl-4-fluorobenzene 
• 459-46-1 4-Fluorobenzyl bromide 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 422270-30-2 2-chloro-1-[4-(4-fluoro-benzyl)-(2R)-2-methyl-piperazin-1-yl]-ethanone 
• 519172-34-0 1-[4-(4-fluoro-benzyl)-(2R)-2-methyl-piperazin-1-yl]-2-hydroxy-ethanone 
• 1229822-65-4 (6,7-dichloro-2,3-dihydro-benzo[1,4]dioxin-2-yl)-[(R)-4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-methanone 
• 1229822-52-9 (6-Chloro-2,3-dihydro-benzo[1,4]dioxin-2-yl)-[(R)-4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-methanone 
• 1229822-80-3 (6-chloro-4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)-[(R)-4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-methanone 
• 1229822-86-9 6-chloro-2-[(R)-4-(4-fluoro-benzyl)-2-methyl-piperazine-1-carbonyl]-4H-benzo[1,4]oxazin-3-one 
• 1229827-89-7 6-chloro-2-{2-[(R)-4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethyl}-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester 
• 1229823-94-2 (6-chloro-7-methoxy-4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)-[(R)-4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-methanone 
• 1229827-31-9 6-chloro-2-[(R)-4-(4-fluoro-benzyl)-2-methyl-piperazine-1-carbonyl]-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester 
• 519173-04-7 2-(4-chloro-2-hydroxy-phenoxy)-1-[4-(4-fluoro-benzyl)-(2R)-2-methyl-piperazin-1-yl]-ethanone 
• 685534-66-1 (E)-1-[(R)-4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-3-(3-nitronaphthalen-2-yl)-propenone 
• 685534-54-7 (E)-3-(2-bromo-4-chlorophenyl)-1-[(R)-4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]propenone 
• 685535-04-0 N-[5-chloro-2-[(E)-3-(R)-4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-3-oxopropenyl-4-(2-methoxyethoxy)-phenyl]-acetamide 
• 685534-88-7 (E)-1-[(R)-4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-3-(6-nitroquinolin-7-yl)-propenone 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists

Three series of novel 2-methylpiperazine derivatives were designed and synthesized using a fragment-assembly strategy. Among them, six compounds (13, 16, 18, 22, 33, and 36) showed potent activity against CCR5 comparable to that of the positive control, maraviroc, in calcium mobilization assay. Moreover, some compounds were selected and further tested for their antiviral activity in HIV-1 single cycle assay. As a result, four compounds (13, 16, 33, and 36) showed antiviral activity at the nanomolar level. Additionally, the potent four compounds showed no cytotoxicity at a concentration of 10 μM.

Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists

Design and synthesis of a series of 3-amino-4-(2-(2-(4-benzylpiperazin-1-yl)-2-oxoethoxy)phenylamino)cyclobutenedione derivatives as novel CCR1 antagonists are described. Structure-activity relationship studies led to the identification of compound 22, which demonstrated potent binding activity, functional antagonism of CCR1 as well as good species cross-reactivity. In addition, compound 22 also showed desirable pharmacokinetic profiles and was selected for in vivo studies in the mouse collagen-induced arthritis model.

Novel sulfonic acid derivatives

A compound of the formula or the pharmaceutically acceptable salt thereof; wherein X, Y, a, b, c, d, R1, R2, R3 and R5 are as defined above useful to treat inflammation and other immune disorders.